Many therapeutic approaches targeting the TNF family, including CD40, OX40, 4-1BB, GITR, and CD27, are currently being actively investigated in clinical trials in various cancers, including GBM, lung cancer, malignant pleural mesothelioma, and spontaneous prostate cancer (7, 10–12). The gene discussed is TNF; the disease is glioblastoma.